Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Defining the Role of Physiotherapy in Palliative Care in Multiple Sclerosis.
Long-term Impact of Early MS Treatment with Interferon Beta-1b (IFNB-1b): Clinical, MRI, Employment, and Patient-Reported Outcomes (PROs) at the 11-Year Follow-up of BENEFIT (BENEFIT 11)
Association between the three functional miR-146a single-nucleotide polymorphisms, rs2910164, rs57095329, and rs2431697, and autoimmune disease susceptibility: A meta-analysis.
Techniques and technologies for the bioanalysis of Sativex(®), metabolites and related compounds.
ForuMS: A Virtual Journal Club for MS Clinicians
American Academy of Neurology Annual Meeting
Live Webcast: Assessing the Potential Impact of New and Emerging Disease-Modifying Therapies on the Initial Treatment and Comprehensive Management of Multiple Sclerosis
The role of stem cell therapy in multiple sclerosis: An overview of the current status of the clinical studies.
PiB and other amyloid-PET tracers for the study of white matter and multiple sclerosis.
Imaging in Pediatric Demyelinating and Inflammatory Diseases of Brain- Part 2.
Mutually enhancing anti-inflammatory activities of dimethyl fumarate and NF-κB inhibitors - Implications for dose-sparing combination therapies.
Akt Regulates Axon Wrapping and Myelin Sheath Thickness in the PNS.
Three-Month Test-Retest Reliability of Center of Pressure Motion During Standing Balance in Individuals with Multiple Sclerosis.
BRIEF: Teva files for Copaxone-Laquinimod patent
Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis.
Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.
Qiagen Webinar: Molecular Mechanisms of Neurodegeneration
Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis.
Reassessing the risk of natalizumab-associated PML.
Genzyme’s once-daily, oral AUBAGIO® (teriflunomide) approved in Argentina for the treatment of relapsing multiple sclerosis
The endocannabinoid system and multiple sclerosis.
Ncx3 gene ablation impairs oligodendrocyte precursor response and increases susceptibility to experimental autoimmune encephalomyelitis.
Optimal combination of FLAIR and T2-weighted MRI for improved lesion contrast in multiple sclerosis.
Novartis announces Russian regulatory approval for Gilenya®, a once-daily oral multiple sclerosis therapy and first in a new class
Episode 11 with Dr. Jack Antel on remyelination and on bedside-to-bench research

Pages